the aid library

LIST OPTIONS

Filter

27751

Direction:

Download (217)

View PDF (197)

Policy brief on tuberculosis-associated disability

World Health Organization WHO (2023) C_WHO

People affected by impairments and disabilities associated with TB are even more likely to belong to marginalized segments of society and are more likely to have their human rights unprotected. The challenges faced by people affected by TB include the consequences of impairment and disability associ... more

External Link

Number of recorded natural disaster events 1900-2023

Our World in Data (2023) CC

The number of global reported natural disaster events in any given year. Note that this largely reflects increases in data reporting, and should notbe used to assess the total number of events.

Operational framework for building climate resilient and low carbon health systems

World Health Organization WHO (2023) C_WHO

This document presents the World Health Organization Operational framework for building climate resilient and low carbon health systems*. ***The framework's goal is to increase the climate resilience of health systems to protect and improve the health of communities in an unstable and changing clima... more

Download (158)

View PDF (167)

Pre-referral treatment with rectal artesunate of children with suspected severe malaria: a field guide

World Health Organization WHO (2023) C_WHO

Prompt, effective antimalarial treatment, and supportive care can substantially reduce the rate of mortality from severe malaria. However, many children in malaria-endemic countries do not have access to health facilities or a qualified health care provider and do not receive the necessary care in a... more

Download (290)

View PDF (386)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Integrating the social determinants of health into health workforce education and training

World Health Organisation (WHO) (2023) C_WHO

Social inequalities are perpetuating unhealthy living and working conditions and behaviours. These causes are commonly called ‘the social determinants of health’. Achieving greater equity in health will demand that the health sector assumes a greater leadership role in addressing social inequali... more

Analysis and use of health facility data: guidance for maternal, newborn, child and adolescent health programme managers

World Health Organisation (WHO) (2023) C_WHO

This guidance describes a catalogue of indicators for maternal, newborn, child and adolescent health (MNCAH) that can be monitored through health management information system data. It is a module of the WHO Toolkit for Routine Health Information Systems (RHIS) Data and links to relevant indicators ... more

Download (131)

View PDF (136)

Roadmap towards ending TB in children and adolescents, 3rd ed

World Health Organisation (WHO) (2023) C_WHO

The Roadmap towards ending TB among children and adolescents, third edition builds on the 2013 and 2018 versions. The 2023 version recognizes the progress made over the past five years and outlines priorities and key actions designed to accelerate progress towards the targets elaborated during the 2... more

Managing epidemics: key facts about major deadly diseases, 2nd edition

World Health Organisation (WHO) (2023) C_WHO

Epidemics and pandemics of infectious diseases are occurring more often, and spreading faster and further than ever, in many different regions of the world. The background factors of this threat are biological, environmental and lifestyle changes, among others. A potentially fatal combination of new... more

Managing epidemics: key facts about major deadly diseases, 2nd edition

World Health Organisation (WHO) (2023) C_WHO

Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, 2nd ed

World Health Organisation (WHO) (2023) C_WHO

Of the more than 10 million people estimated to have fallen ill with tuberculosis (TB) in 2022, just over 400 000 people developed TB resistant to rifampicin (RIF), and 1.3 million people developed TB resistant isoniazid (INH). Drug resistance must be detected rapidly and accurately to initiate appr... more

Zanzibar's victory against Cholera Epidemic

World Health Organization WHO (2023) C_WHO

Response to the Periodic Epidemic

Download (121)

View PDF (254)

WHO Malawi Annual Report 2022

World Health Organization WHO (2023) C_WHO

Annual Report WHO

Download (125)

View PDF (447)

Natural Disasters

Berger N., The MEDBOX Team (2023) CC

Daily news report natural catastrophies more and more frequently. The reports include earthquakes, floods, volcanos, famines and droughts. The number of fatalities from natural disasters can vary grately from year to year. Looking at the average over the last ten years, about 45,000 people died each... more

External Link

Climate-change migrants: what can be done?

The Economist (2023) CC

Video

Download (144)

View PDF (146)

Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders

World Health Organization WHO (2023) C_WHO

The mhGAP guideline supports countries to strengthen capacity to deal with the growing burden of mental, neurological and substance use (MNS) conditions and narrow the treatment gap. This new edition includes 30 updated and 18 new recommendations, alongside 90 pre-existing recommendations. This is t... more

National Strategic Plan for Ending TB 2020-2024

World Health Organization WHO (2023) C_WHO

World Health Organization. Country Office for Timor-Leste. (‎2020)‎. National strategic plan for ending TB 2020--2024. World Health Organization. Country Office for Timor-Leste.

Download (146)

View PDF (132)

Laboratory and point-of-care diagnostic testing for sexually transmitted infections, including HIV

World Health Organization WHO (2023) C_WHO

This updated manual provides a basic understanding of the principles of laboratory and point-of-care (POC) testing in the context of screening and diagnostic approaches, as well as antimicrobial susceptibility testing, as components of sexually transmitted infections (STIs) control. As with previous... more

Download (208)

View PDF (312)

Protecting maternal, newborn and child health from the impacts of climate change: call for action

World Health Organization WHO (2023) C_WHO

Climate hazards, including extreme heat, are associated with increased risks of developing complications that lead to adverse maternal and perinatal outcomes. These may include multiple causes of maternal and neonatal morbidity and mortality such as gestational diabetes, hyper tensive disorders of p... more

Opportunities for transition to clean household energy in Nepal

World Health Organization WHO (2023) C_WHO

According to the 2016 Nepal Demographic and Health Survey, 66% of Nepali households use mainly solid fuel for cooking on inefficient stoves. Incomplete fuel combustion of solid fuels emits greenhouse gases and harmful smoke, contributing to climate change, forest degradation, ill health and preventa... more